text:
|Publication number
|Publication type
|Application number
|Publication date
|Oct 18, 2011
|Filing date
|Aug 23, 2006
|Priority date
|May 11, 2001
|Fee status
|Also published as
|Publication number
|Araz A. Raoof, Mangaraju Gudipati, David C. Bibby, Susan Weinbach
|Original Assignee
|Isis Pharmaceuticals, Inc.
|Export Citation
|BiBTeX, EndNote, RefMan
|Patent Citations (74), Non-Patent Citations (28), Classifications (45), Legal Events (1)
|External Links: USPTO, USPTO Assignment, Espacenet
This application is a continuation of U.S. application Ser. No. 10/145,181, filed May 13, 2002, which is hereby incorporated by reference, which is based on and claims priority to U.S. Provisional Application No. 60/290,436, filed May 11, 2001.
The present invention was made as a result of activities undertaken within the scope of a written joint research agreement between Elan Corporation, PLC, Elan International Services, Ltd., Isis Pharmaceuticals, Inc., and Orasense Ltd.
The present invention relates to permeation enhancers that are useful in the administration of a drug.
Drug delivery systems generally involve a permeation step followed by absorption into the circulatory system. For example, a drug can be applied through the skin by use of a transdermal patch which comprises a drug and a film or fabric and which is adhered to the outer skin of the patient. Drugs may also be delivered across a mucous membrane or other cellular membrane (collectively "transmucosal"), for example, by: (A) aerosol delivery of the drug to the nose or lungs; (B) oral ingestion of the drug followed by permeation through the gastrointestinal wall; and (C) the dissolution of lozenges or pills held between the cheek and gum or under the tongue followed by transport through the membranes of the mouth.
During the early development of transdermal delivery systems, investigators found that the oily, hydrophobic nature of the skin reduces significantly the absorption rate of aqueous drug solutions or dispersions. Thus, the natural barrier properties of skin, which protect the body against the ingress of foreign substances, act also as barriers to applied drugs, thereby reducing their rate of permeation and ultimately their bioavailability. Problems are encountered also in delivering drugs in a satisfactory way by transmucosal means. The rate of drug permeation is an important factor in achieving bioavailability and pharmaceutically useful concentrations of the drug at the target membrane. It is not surprising that considerable effort has been dedicated toward the objective of enhancing the rate of drug permeation through the skin or by transmucosal means. Examples of such efforts are summarized below.
U.S. Pat. No. 5,854,281 (Uekama, et al.) teaches the use of straight chain fatty acids, salts, and esters thereof to enhance the percutaneous permeability of prostaglandin. U.S. Pat. Nos. 5,952,000 and 5,912,009 (Venkateshwaran, et al.) disclose drug delivery systems that are enhanced by the presence of a fatty acid ester of lactic acid (or salts thereof) and a fatty acid ester (or salts thereof) of glycolic acid respectively. The use of glycerides of fatty acids to enhance the skin permeation of a biologically active pergolide is disclosed in U.S. Pat. No. 6,001,390 (Yum, et al.). U.S. Pat. No. 4,789,547 teaches the enhancement of drug permeation through the skin by a saturated or unsaturated fatty acid in a solvent such as propylene glycol. Published PCT application WO00/22909 discloses oral delivery systems for pharmaceutical or other biologically active substances wherein the pharmaceutical or other substance is coated or complexed with a carboxylic acid to enable the substance to transit the stomach and to be absorbed in the intestine. The coating or complexing is achieved by means of co-precipitation from an acidic solution of the active substance and carboxylic acid, which is described as having from nine to 30 carbon atoms in a straight or branched chain, saturated or unsaturated, acyclic or cyclic structure and further substituted or unsubstituted with functional groups such as steroid rings, phenyl groups and the like. WO00/22909 discloses specific examples of complexes formed from the straight chain, saturated or unsaturated or steroidal carboxylic acids, dodecanoic acid, tetradecanoic acid, hexadecanoic acid, octadecanoic acid, oleic acid. palmitoleic acid, ricinoleic acid and fusidic acid.
Investigators continue to seek ways to safely and effectively administer pharmaceutical agents by transmucosal or transdermal routes. Obstacles to these goals are the complexity and variability in the properties of the various types of membranes and the skin. Furthermore, for large molecule pharmaceutical agents, for example, antisense oligonucleotides, passage through these various membranes and the skin is particularly difficult. In light of the recognized need to overcome the natural barrier properties of bodily membranes and skin in achieving bioavailability of antisense oligonucleotides, the present invention relates to the provision of a class of compounds that enhance the permeation of antisense oligonucleotides for delivery to a patient.
In accordance with the present invention, there is provided a composition comprising an antisense compound and a compound which is effective in enhancing the bioavailability of said antisense compound and which comprises a multi-carbon backbone having a functional group and also one or more side chains which have one or more carbon atoms and, optionally, one or more functional groups. A preferred class of bioavailability-enhancing compounds comprises a compound of Formula I below.
wherein, Q is
(1) a partially or completely neutralized —COOH, or
(2) a partially or completely neutralized —SO3H, or
(3) a mono- or di-substituted alkyl or alkenyl group having one to about twelve carbon atoms, the substituent(s) thereof being a partially or completely neutralized —COOH or partially or completely neutralized —SO3H;
R1 and R2 are independently
(1) an unsubstituted alkyl or alkenyl group having one to about twelve carbon atoms, or
(2) a substituted alkyl or alkenyl group having one to about twelve carbon atoms, the substituent thereof being selected from the group consisting of
In preferred form, the antisense compound comprises an antisense oligonucleotide. Preferably, the antisense oligonucleotide comprises a modification selected from the group consisting of base modifications, internucleotide linkage modifications and sugar moiety modifications. In a preferred form, the antisense oligonucleotide has a modified sugar moiety wherein the modification is a 2′-O-(2-methoxyethyl) modification. Also, in preferred form, the enhancer comprises a compound in which Q is partially or completely neutralized —COOH.
Another aspect of the present invention includes a method of treating a condition in a patient comprising administering to the patient a composition which comprises an antisense oligonucleotide in a pharmaceutically effective amount and a permeation enhancer of Formula I above in an enhancing-effective amount.
As explained below, a particular advantage of the present invention is that it provides to the medical and pharmaceutical professions a compound that enhances the permeation of an antisense oligonucleotide into and through the intestinal barrier of a subject.
As mentioned above, the composition of the present invention comprises an antisense compound, a compound that is characterized herein as a permeation enhancer, and, optionally, a vehicle. In selecting a permeation enhancer from among the compounds represented by Formula I, consideration is given to both the nature of the antisense compound employed and to the tendency of the target membrane or skin to absorb the antisense compound. As will become evident from the following discussion, there is included within the class of enhancer compounds of the present invention compounds that have a wide range of hydrophobic-hydrophilic properties and that may be described as branched chain compounds.
The compounds of Formula I comprise a multi-carbon backbone having a functional group and also a side chain(s) which has one or more carbon atoms and, optionally, one or more functional groups. The compounds are therefore distinguished from the straight chain carboxylic acids reported in the literature as having permeation enhancer properties. Each of R1 and R2 of Formula I represents an unsubstituted alkyl or unsubstituted alkenyl group having 1 to about 12 carbon atoms or a substituted alkyl or substituted alkenyl group having 1 to about 12 carbon atoms, or one of R1 or R2 can be a substituted alkyl or substituted alkenyl group having 1 to about 12 carbon atoms and the other an unsubstituted alkyl or unsubstituted alkenyl group. Each of R1 and R2 of Formula I may be a straight chain, branched, or cyclo-aliphatic group.
In addition, one of R1 or R2 can be an alkyl group and the other an alkenyl group. Examples of alkyl groups are methyl, ethyl, isopropyl, hexyl, octyl, decyl, and dodecyl. Preferably, the alkyl group has at least about 4 to about 12 carbon atoms. Examples of alkenyl groups are octenyl, pentenyl, and dodecenyl. Preferably, the alkenyl group has at least about 4 to about 12 carbon atoms.
Also, in preferred form, the sum of the carbon atoms in R1 and R2 is at least about 16. In a particularly preferred form of the invention, R1 is alkyl and R2 is alkyl. For those enhancers in which R1 and/or R2 includes a substituted alkyl or substituted alkenyl group, it is preferred that the substituent thereof is a hydroxyl group.
As set forth in Formula I, enhancer compounds useful in the present invention can include a partially or completely neutralized —COOH or —SO3H group. As used herein, the term "neutralized" means the reaction product of the carboxylic acid or sulfonic acid with a base that is present in an amount sufficient to react with all of the acid. As used herein, the term "partially neutralized" means the reaction product of the carboxylic or sulfonic acid with an amount of base that reacts with less than all of the acid, but with at least about 50% of the acid. Examples of bases that can be used are sodium hydroxide, sodium carbonate, potassium hydroxide, magnesium hydroxide, calcium hydroxide, ammonium hydroxide, and trialkyl amine. Preferably, -Q of Formula I is the sodium salt of —COOH. For those enhancers where -Q of Formula I is a substituted alkyl or substituted alkenyl group, the following are examples of such groups: methyl, hexyl, octyl, and dodecyl. Preferably, the total number of carbon atoms in the alkyl or alkenyl group is about one to about 12, with an alkyl group being preferred.
In a preferred group of compounds of Formula I, R1 is C6-C12 alkyl, R2 is C4-C10 alkyl, and -Q is neutralized —COOH. Particularly preferred permeation enhancers are compounds represented by Formula I wherein R1 is C6-8 alkyl, R2is is C8-10 alkyl, and -Q is —COONa.
A preferred enhancer compound useful in the present invention comprises the sodium salt of a carboxylic acid of Formula I in which R1 is an alkyl group having ten carbon atoms (C10H21) and R2 is an alkyl group having eight carbon atoms (C8H17) sodium 2-n-octyl-dodecanoate. Other preferred enhancer compounds include sodium 2-n-hexyl-decanoate and sodium 2-n-butyl-octanoate.
The enhancer compounds useful in the present invention can include a chiral center. When the enhancer compound includes a chiral center, it may be used as a racemic mixture of optical isomers, or optionally as the essentially pure D or L isomers of the enhancer compound.
Enhancer compounds within the scope of the present invention are known. It will be recognized that preparation of the enhancer compounds is well within the purview of one of ordinary skill in the art. Speaking generally, the enhancer carboxylic acids useful in the present invention can be prepared according to known preparative methods. Non-limiting examples of preparative methods include the oxidative cleavage of an appropriately unsaturated hydrocarbon with a strong oxidizing agent and the saponification of a corresponding ester. A non-limiting example of a typical ester is the glyceride of the desired acid.
Neutralization of a carboxylic acid or sulfonic acid with an alkali such as sodium hydroxide is generally carried out by adding the alkali to a stirred solution of the acid dissolved in water or a mixture of water and alcohol.
The enhancer of Formula I can be mono-functional or multi-functional. The degree of functionality and length of the carbon chain are related to the hydrophilic-hydrophobic (lipophilic) nature of the enhancer compounds. In general, the higher the degree of functionality, the more hydrophilic is the compound. Also, speaking to generally, the greater the number of carbon atoms in the compound, the more hydrophobic the compound is. Improved delivery of antisense oligonucleotides can be achieved when the hydrophobic-hydrophilic balance of the enhancer is matched appropriately to the drug and to the targeted tissue. Selecting -R1, -R2 and -Q with relatively long carbon chains can provide enhancers having a relatively high degree of hydrophobicity. In contrast, enhancers with relatively short carbon chains and with multi-functional groups have a relatively high degree of hydrophilicity.
The composition of the present invention may comprise an enhancer compound of Formula I in admixture with one or more other enhancers, for example, a straight chain fatty acid, an ester or salt thereof, or compounds that promote the formation of liposomes, or a micro emulsion. When additional enhancer compounds are used, they may be present in a weight ratio of up to about 99 parts of the additional enhancer for each part of a salt of Formula 1. The range of mixtures of an additional enhancer:salt of Formula 1 by weight ratio which are preferred are from about 99:1 to about 1:99.
In preferred form, a composition comprising an enhancer compound of the present invention (those of Formula I) and additional other enhancer compounds, the enhancer compounds of Formula I comprise no more than by weight about 50% of the enhancer compounds present.
When enhancer compounds of the present invention are mixed with other enhancer compounds in formulations used in connection with delivery of a drug comprising an antisense nucleotide, typically the enhancer compounds of Formula I comprises, by weight, at least about 10% of the enhancer compounds present in the formulations.
The compositions of the present invention comprise also antisense compounds particularly antisense oligonucleotides used to treat disease states that result from undesirable levels of protein production and/or activity in the body. These antisense compounds specifically hybridize with one or more target nucleic acids encoding a protein involved in a given disease state.
As used herein, the term "target nucleic acid" encompasses DNA encoding a protein, RNA (including pre-mRNA and mRNA) transcribed from such DNA, and also cDNA derived from such RNA. The specific hybridization of an antisense compound with its target nucleic acid interferes with the normal function of the nucleic acid. This modulation of function of a target nucleic acid by compounds that specifically hybridize to it is generally referred to as "antisense". The functions of DNA to be interfered with include replication and transcription. The functions of RNA to be interfered with include all vital functions such as, for example, translocation of the RNA to the site of protein translation, translation of protein from the RNA, splicing of the RNA to yield one or more mRNA species, and catalytic activity which may be engaged in or facilitated by the RNA. The overall effect of such interference with target nucleic acid function is modulation of the expression of the protein encoded by the nucleic acid. In the context of the present invention, "modulation" means either an increase (stimulation) or a decrease (inhibition) in the expression of a gene. In the context of the present invention, inhibition is the preferred form of modulation of gene expression and mRNA is a preferred target.
It is preferred to target specific nucleic acids with the antisense oligonucleotides of the present invention. "Targeting" an antisense compound to a particular nucleic acid, in the context of this invention, is a multistep process. The process usually begins with the identification of a nucleic acid sequence whose function is to be modulated. This may be, for example, a cellular gene (or mRNA transcribed from the gene) whose expression is associated with a particular disorder or disease state, or a nucleic acid molecule from an infectious agent. The targeting process also includes determination of a site or sites within this gene for the antisense interaction to occur such that the desired effect, e.g., detection or modulation of expression of the protein, will result. Within the context of the present invention, a preferred intragenic site is the region encompassing the translation initiation or termination codon of the open reading frame (ORF) of the gene. Since, as is known in the art, the translation initiation codon is typically 5′-AUG (in transcribed mRNA molecules; 5′-ATG in the corresponding DNA molecule), the translation initiation codon is also referred to as the "AUG codon," the "start codon" or the "AUG start codon". A minority of genes have a translation initiation codon having the RNA sequence 5′-GUG, 5′-UUG or 5′-CUG, and 5′-AUA, 5′-ACG and 5′-CUG have been shown to function in vivo. Thus, the terms "translation initiation codon" and "start codon" can encompass many codon sequences, even though the initiator amino acid in each instance is typically methionine (in eukaryotes) or formylmethionine (in prokaryotes). It is also known in the art that eukaryotic and prokaryotic genes may have two or more alternative start codons, any one of which may be preferentially utilized for translation initiation in a particular cell type or tissue, or under a particular set of conditions. In the context of the invention, "start codon" and "translation initiation codon" refer to the codon or codons that are used in vivo to initiate translation of an mRNA molecule transcribed from a gene encoding a protein, regardless of the sequence(s) of such codons.
It is also known in the art that a translation termination codon (or "stop codon") of a gene may have one of three sequences, i.e., 5′-UAA, 5′-UAG and 5′-UGA (the corresponding DNA sequences are 5′-TAA, 5′-TAG and 5′-TGA, respectively). The terms "start codon region" and "translation initiation codon region" refer to a portion of such an mRNA or gene that encompasses from about 25 to about 50 contiguous nucleotides in either direction (i.e., 5′ or 3′) from a translation initiation codon. Similarly, the terms "stop codon region" and "translation termination codon region" refer to a portion of such an mRNA or gene that encompasses from about 25 to about 50 contiguous nucleotides in either direction (i.e., 5′ or 3′) from a translation termination codon.
The open reading frame (ORF) or "coding region," which is known in the art to refer to the region between the translation initiation codon and the translation termination codon, is also a region which may be targeted effectively. Other target regions include the 5′ untranslated region (5′UTR), known in the art to refer to the portion of an mRNA in the 5′ direction from the translation initiation codon, and thus including nucleotides between the 5′ cap site and the translation initiation codon of an mRNA or corresponding nucleotides on the gene, and the 3′ untranslated region (3′UTR), known in the art to refer to the portion of an mRNA in the 3′ direction from the translation termination codon, and thus including nucleotides between the translation termination codon and 3′ end of an mRNA or corresponding nucleotides on the gene. The 5′ cap of an mRNA comprises an N7-methylated guanosine residue joined to the 5′-most residue of the mRNA via a 5′-5′ triphosphate linkage. The 5′ cap region of an mRNA is considered to include the 5′ cap structure itself as well as the first 50 nucleotides adjacent to the cap. The 5′ cap region may also be a preferred target region.
Although some eukaryotic mRNA transcripts are directly translated, many contain one or more regions, known as "introns," which are excised from a transcript before it is translated. The remaining (and therefore translated) regions are known as "exons" and are spliced together to form a continuous mRNA sequence. mRNA splice sites, i.e., intron-exon junctions, may also be preferred target regions, and are particularly useful in situations where aberrant splicing is implicated in disease, or where an overproduction of a particular mRNA splice product is implicated in disease. Aberrant fusion junctions due to rearrangements or deletions are also preferred targets. It has also been found that introns can also be effective, and therefore preferred, target regions for antisense compounds targeted, for example, to DNA or pre-mRNA.
Once one or more target sites have been identified, oligonucleotides are chosen which are sufficiently complementary to the target, i.e., hybridize sufficiently well and with sufficient specificity, to give the desired effect.
In the context of this invention, "hybridization" means hydrogen bonding, which may be Watson-Crick, Hoogsteen or reversed Hoogsteen hydrogen bonding, between complementary nucleoside or nucleotide bases. For example, adenine and thymine are complementary nucleobases which pair through the formation of hydrogen bonds. "Complementary," as used herein, refers to the capacity for precise pairing between two nucleotides. For example, if a nucleotide at a certain position of an oligonucleotide is capable of hydrogen bonding with a nucleotide at the same position of a DNA or RNA molecule, then the oligonucleotide and the DNA or RNA are considered to be complementary to each other at that position. The oligonucleotide and the DNA or RNA are complementary to each other when a sufficient number of corresponding positions in each molecule are occupied by nucleotides which can hydrogen bond with each other. Thus, "specifically hybridizable" and "complementary" are terms which are used to indicate a sufficient degree of complementarity or precise pairing such that stable and specific binding occurs between the oligonucleotide and the DNA or RNA target. It is understood in the art that the sequence of an antisense oligonucleotide need not be 100% complementary to that of its target nucleic acid to be specifically hybridizable. An antisense oligonucleotide is specifically hybridizable when binding of the compound to the target DNA or RNA molecule interferes with the normal function of the target DNA or RNA to cause a loss of utility, and there is a sufficient degree of complementarity to avoid non-specific binding of the antisense oligonucleotide to non-target sequences under conditions in which specific binding is desired, i.e., under physiological conditions in the case of in vivo assays or therapeutic treatment, and in the case of in vitro assays, under conditions in which the assays are performed.
While antisense oligonucleotides are a preferred form of antisense compound, the present invention comprehends other oligomeric antisense compounds, including but not limited to oligonucleotide mimetics such as are described below. The antisense compounds in accordance with this invention preferably comprise from about 8 to about 50 nucleobases (i.e. from about 8 to about 50 linked nucleosides). Particularly preferred antisense compounds are antisense oligonucleotides, even more preferably those comprising from about 12 to about 25 nucleobases. Even more preferably, the antisense oligonucleotides comprise from about 15 to about 20 nucleobases. In a most preferred embodiment, the antisense oligonucleotides of the present invention comprise about 20 nucleobases. Antisense compounds include ribozymes, external guide sequence (EGS) oligonucleotides (oligozymes), and other short catalytic RNAs or catalytic oligonucleotides which hybridize to the target nucleic acid and modulate its expression.
In the context of this invention, the term "oligonucleotide" refers to an oligomer or polymer of ribonucleic acid (RNA) or deoxyribonucleic acid (DNA) or mimetics thereof. This term includes oligonucleotides composed of naturally-occurring nucleobases, sugars and covalent internucleoside (backbone) linkages as well as oligonucleotides having non-naturally-occurring portions which function similarly. Such modified or substituted oligonucleotides are often preferred over native forms because of desirable properties such as, for example, enhanced cellular uptake, enhanced affinity for nucleic acid target and increased stability in the presence of nucleases.
Specific examples of preferred antisense compounds useful in this invention include oligonucleotides containing modified backbones or non-natural internucleoside linkages. As defined in this specification, oligonucleotides having modified backbones include those that retain a phosphorus atom in the backbone and those that do not have a phosphorus atom in the backbone. For the purposes of this specification, and as sometimes referenced in the art, modified oligonucleotides that do not have a phosphorus atom in their internucleoside backbone can also be considered to be oligonucleosides.
Preferred modified oligonucleotide backbones include, for example, phosphorothioates, chiral phosphorothioates, phosphorodithioates, phosphotriesters, aminoalkylphosphotriesters, methyl and other alkyl phosphonates including 3′-alkylene phosphonates, 5′-alkylene phosphonates and chiral phosphonates, phosphinates, phosphoramidates including 3′-amino phosphoramidate and aminoalkylphosphoramidates, thionophosphoramidates, thionoalkylphosphonates, thionoalkylphosphotriesters, selenophosphates and boranophosphates having normal 3′-5′ linkages, 2′-5′ linked analogs of these, and those having inverted polarity wherein one or more internucleotide linkages is a 3′ to 3′, 5′ to 5′ or 2′ to 2′ linkage. Preferred oligonucleotides having inverted polarity comprise a single 3′ to 3′ linkage at the 3′-most internucleotide linkage i.e. a single inverted nucleoside residue which may be abasic (the nucleobase is missing or has a hydroxyl group in place thereof). Various salts, mixed salts and free acid forms are also included.
Representative United States patents that teach the preparation of the above phosphorus-containing linkages include, but are not limited to, U.S. Pat. Nos. 3,687,808; 4,469,863; 4,476,301; 5,023,243; 5,177,196; 5,188,897; 5,264,423; 5,276,019; 5,278,302; 5,286,717; 5,321,131; 5,399,676; 5,405,939; 5,453,496; 5,455,233; 5,466,677; 5,476,925; 5,519,126; 5,536,821; 5,541,306; 5,550,111; 5,563,253; 5,571,799; 5,587,361; 5,194,599; 5,565,555; 5,527,899; 5,721,218; 5,672,697 and 5,625,050, each of which is herein incorporated by reference.
Preferred modified oligonucleotide backbones that do not include a phosphorus atom therein have backbones that are formed by short chain alkyl or cycloalkyl internucleoside linkages, mixed heteroatom and alkyl or cycloalkyl internucleoside linkages, or one or more short chain heteroatomic or heterocyclic internucleoside linkages. These include those having morpholino linkages (formed in part from the sugar portion of a nucleoside); siloxane backbones; sulfide, sulfoxide and sulfone backbones; formacetyl and thioformacetyl backbones; methylene formacetyl and thioformacetyl backbones; riboacetyl backbones; alkene containing backbones; sulfamate backbones; methyleneimino and methylenehydrazino backbones; sulfonate and sulfonamide backbones; amide backbones; and others having mixed N, O, S and CH2 component parts.
Representative United States patents that teach the preparation of the above oligonucleosides include, but are not limited to, U.S. Pat. Nos. 5,034,506; 5,166,315; 5,185,444; 5,214,134; 5,216,141; 5,235,033; 5,264,562; 5,264,564; 5,405,938; 5,434,257; 5,466,677; 5,470,967; 5,489,677; 5,541,307; 5,561,225; 5,596,086; 5,602,240; 5,610,289; 5,602,240; 5,608,046; 5,610,289; 5,618,704; 5,623,070; 5,663,312; 5,633,360; 5,677,437; 5,792,608; 5,646,269 and 5,677,439, each of which is herein incorporated by reference.
In other preferred oligonucleotide mimetics, both the sugar and the internucleoside linkage, i.e., the backbone, of the nucleotide units are replaced with novel groups. The base units are maintained for hybridization with an appropriate nucleic acid target compound. One such oligomeric compound, an oligonucleotide mimetic that has been shown to have excellent hybridization properties, is referred to as a peptide nucleic acid (PNA). In PNA compounds, the sugar-backbone of an oligonucleotide is replaced with an amide containing backbone, in particular an aminoethylglycine backbone. The nucleobases are retained and are bound directly or indirectly to aza nitrogen atoms of the amide portion of the backbone.
Representative-United States patents that teach the preparation of PNA compounds include, but are not limited to, U.S. Pat. Nos. 5,539,082; 5,714,331; and 5,719,262, each of which is herein incorporated by reference. Further teaching of PNA compounds can be found in Nielsen et al., Science, 1991, 254, 1497-1500.
Most preferred embodiments of the invention are oligonucleotides with phosphorothioate backbones and oligonucleosides with heteroatom backbones, and in particular —CH2—NH—O—CH2—, —CH2—N(CH3)—O—CH2— [known as a methylene(methylimino) or MMI backbone], —CH2—O—N(CH3)—CH2—, —CH2—N(CH3)—N(CH3)—CH2— and —O—N(CH3)—CH2—CH2— [wherein the native phosphodiester backbone is represented as —O—P—O—CH2—] of the above referenced U.S. Pat. No. 5,489,677, and the amide backbones of the above referenced U.S. Pat. No. 5,602,240. Also preferred are oligonucleotides having morpholino backbone structures of the above-referenced U.S. Pat. No. 5,034,506.
Modified oligonucleotides may also contain one or more substituted sugar moieties. Preferred oligonucleotides comprise one of the following at the 2′ position: OH; F; O-, S-, or N-alkyl; O-, S-, or N-alkenyl; O-, S- or N-alkynyl; or O-alkyl-O-alkyl, wherein the alkyl, alkenyl and alkynyl may be substituted or unsubstituted C1 to C10 alkyl or C2 to C10 alkenyl and alkynyl. Particularly preferred are O[(CH2)nO]mCH3, O(CH2)nOCH3, O(CH2)nNH2, O(CH2)nCH3, O(CH2)nONH2, and O(CH2)nON[(CH2)nCH3)]2, where n and m are from 1 to about 10. Other preferred oligonucleotides comprise one of the following at the 2′ position: C1 to C10 lower alkyl, substituted lower alkyl, alkenyl, alkynyl, alkaryl, aralkyl, O-alkaryl or O-aralkyl, SH, SCH3, OCN, Cl, Br, CN, CF3, OCF3, SOCH3, SO2CH3, ONO2, NO2, N3, NH2, heterocycloalkyl, heterocycloalkaryl, aminoalkylamino, polyalkylamino, substituted silyl, an RNA cleaving group, a reporter group, an intercalator, a group for improving the pharmacokinetic properties of an oligonucleotide, or a group for improving the pharmacodynamic properties of an oligonucleotide, and other substituents having similar properties. A preferred modification includes 2′-methoxyethoxy (2-O—CH2CH2OCH3, also known as 2′-O-(2-methoxyethyl) or 2′-MOE) (Martin et al., Helv. Chim. Acta, 1995, 78, 486-504) i.e., an alkoxyalkoxy group. A further preferred modification includes 2′-dimethylaminooxyethoxy, i.e., a O(CH2)2ON(CH3)2 group, also known as 2′-DMAOE, and 2′-dimethylaminoethoxyethoxy (also known in the art as 2′-dimethylaminoethoxyethyl or 2′-DMAEOE), i.e., 2′-O—CH2—O—CH2—N(CH2)2.
A further preferred modification includes Locked Nucleic Acids (LNAs) in which the 2′-hydroxyl group is linked to the 3′ or 4′ carbon atom of the sugar ring thereby forming a bicyclic sugar moiety. The linkage is preferably a methelyne (—CH2—)n group bridging the 2′ oxygen atom and the 4′ carbon atom wherein n is 1 or 2. LNAs and preparation thereof are described in WO 98/39352 and WO 99/14226.
Other preferred modifications include 2′-methoxy (2′-O—CH3), 2′-aminopropoxy (2′-OCH2CH2CH2NH2), 2′-allyl (2′-CH2—CH═CH2), 2′-O-allyl (2′-O—CH2—CH═CH2) and 2′-fluoro (2′-F). The 2′-modification may be in the arabino (up) position or ribo (down) position. A preferred 2′-arabino modification is 2′-F. Similar modifications may also be made at other positions on the oligonucleotide, particularly the 3′ position of the sugar on the 3′ terminal nucleotide or in 2′-5′ linked oligonucleotides and the 5′ position of 5′ terminal nucleotide. Oligonucleotides may also have sugar mimetics such as cyclobutyl moieties in place of the pentofuranosyl sugar. Representative United States patents that teach the preparation of such modified sugar structures include, but are not limited to, U.S. Pat. Nos. 4,981,957; 5,118,800; 5,319,080; 5,359,044; 5,393,878; 5,446,137; 5,466,786; 5,514,785; 5,519,134; 5,567,811; 5,576,427; 5,591,722; 5,597,909; 5,610,300; 5,627,053; 5,639,873; 5,646,265; 5,658,873; 5,670,633; 5,792,747; and 5,700,920, each of which is herein incorporated by reference in its entirety.
Oligonucleotides may also include nucleobase (often referred to in the art simply as "base") modifications or substitutions. As used herein, "unmodified" or "natural" nucleobases include the purine bases adenine (A) and guanine (G), and the pyrimidine bases thymine (T), cytosine (C) and uracil (U). Modified nucleobases include other synthetic and natural nucleobases such as 5-methylcytosine (5-me-C), 5-hydroxymethyl cytosine, xanthine, hypoxanthine, 2-aminoadenine, 6-methyl and other alkyl derivatives of adenine and guanine, 2-propyl and other alkyl derivatives of adenine and guanine, 2-thiouracil, 2-thiothymine and 2-thiocytosine, 5-halouracil and cytosine, 5-propynyl (—C C—CH3) uracil and cytosine and other alkynyl derivatives of pyrimidine bases, 6-azo uracil, cytosine and thymine, 5-uracil (pseudouracil), 4-thiouracil, 8-halo, 8-amino, 8-thiol, 8-thioalkyl, 8-hydroxyl and other 8-substituted adenines and guanines, 5-halo particularly 5-bromo, 5-trifluoromethyl and other 5-substituted uracils and cytosines, 7-methylguanine and 7-methyladenine, 2-F-adenine, 2-amino-adenine, 8-azaguanine and 8-azaadenine, 7-deazaguanine and 7-deazaadenine and 3-deazaguanine and 3-deazaadenine. Further modified nucleobases include tricyclic pyrimidines such as phenoxazine cytidine (1H-pyrimido[5,4-b][1,4]benzoxazin-2(3H)-one), phenothiazine cytidine (1H-pyrimido[5,4-b][1,4]benzothiazin-2(3H)-one), G-clamps such as a substituted phenoxazine cytidine (e.g. 9-(2-aminoethoxy)-H-pyrimido[5,4-b][1,4]benzoxazin-2(3H)-one), carbazole cytidine (2H-pyrimido[4,5-b]indol-2-one), pyridoindole cytidine (H-pyrido[3′,2′:4,5]pyrrolo[2,3-d]pyrimidin-2-one). Modified nucleobases may also include those in which the purine or pyrimidine base is replaced with other heterocycles, for example 7-deaza-adenine, 7-deazaguanosine, 2-aminopyridine and 2-pyridone. Further nucleobases include those disclosed in U.S. Pat. No. 3,687,808, those disclosed in The Concise Encyclopedia Of Polymer Science And Engineering, pages 858-859, Kroschwitz, J. I., ed. John Wiley & Sons, 1990, those disclosed by Englisch et al., Angewandte Chemie, International Edition, 1991, 30, 613, and those disclosed by Sanghvi, Y. S., Chapter 15, Antisense Research and Applications, pages 289-302, Crooke, S. T. and Lebleu, B. ed., CRC Press, 1993. Certain of these nucleobases are particularly useful for increasing the binding affinity of the oligomeric compounds of the invention. These include 5-substituted pyrimidines, 6-azapyrimidines and N-2, N-6 and O-6 substituted purines, including 2-aminopropyladenine, 5-propynyluracil and 5-propynylcytosine. 5-methylcytosine substitutions have been shown to increase nucleic acid duplex stability by 0.6-1.2.degree. C. (Sanghvi, Y. S., Crooke, S. T. and Lebleu, B., eds., Antisense Research and Applications, CRC Press, Boca Raton, 1993, pp. 276-278) and are presently preferred base substitutions, even more particularly when combined with 2′-O-(2-methoxyethyl) sugar modifications.
Representative United States patents that teach the preparation of certain of the above noted modified nucleobases as well as other modified nucleobases include, but are not limited to, the above noted U.S. Pat. No. 3,687,808, as well as U.S. Pat. Nos. 4,845,205; 5,130,302; 5,134,066; 5,175,273; 5,367,066; 5,432,272; 5,457,187; 5,459,255; 5,484,908; 5,502,177; 5,525,711; 5,552,540; 5,587,469; 5,594,121, 5,596,091; 5,614,617; 5,645,985; 5,830,653; 5,763,588; 6,005,096; 5,681,941, and 5,750,692, each of which is herein incorporated by reference.
Another modification of the oligonucleotides of the invention involves chemically linking to the oligonucleotide one or more moieties or conjugates which enhance the activity, cellular distribution or cellular uptake of the oligonucleotide. The compounds of the invention can include conjugate groups covalently bound to functional groups such as primary or secondary hydroxyl groups. Conjugate groups of the invention include intercalators, reporter molecules, polyamines, polyamides, polyethylene glycols, polyethers, groups that enhance the pharmacodynamic properties of oligomers, and groups that enhance the pharmacokinetic properties of oligomers. Typical conjugates groups include cholesterols, lipids, phospholipids, biotin, phenazine, folate, phenanthridine, anthraquinone, acridine, fluoresceins, rhodamines, coumarins, and dyes. Groups that enhance the pharmacodynamic properties, in the context of this invention, include groups that improve oligomer uptake, enhance oligomer resistance to degradation, and/or strengthen sequence-specific hybridization with RNA. Groups that enhance the pharmacokinetic properties, in the context of this invention, include groups that improve oligomer uptake, distribution, metabolism or excretion. Representative conjugate groups are disclosed in International Patent Application PCT/US92/09196, filed Oct. 23, 1992 the entire disclosure of which is incorporated herein by reference. Conjugate moieties include but are not limited to lipid moieties such as a cholesterol moiety (Letsinger et al., Proc. Natl. Acad. Sci. USA, 1989, 86, 6553-6556), cholic acid (Manoharan et al., Bioorg. Med. Chem. Let., 1994, 4, 1053-1060), a thioether, e.g., hexyl-S-tritylthiol (Manoharan et al., Ann. N.Y. Acad. Sci., 1992, 660, 306-309; Manoharan et al., Bioorg. Med. Chem. Let., 1993, 3, 2765-2770), a thiocholesterol (Oberhauser et al., Nucl. Acids Res., 1992, 20, 533-538), an aliphatic chain, e.g., dodecandiol or undecyl residues (Saison-Behmoaras et al., EMBO J., 1991, 10, 1111-1118; Kabanov et al., FEBS Lett., 1990, 259, 327-330; Svinarchuk et al., Biochimie, 1993, 75, 49-54), a phospholipid, e.g., di-hexadecyl-rac-glycerol or triethylammonium 1,2-di-O-hexadecyl-rac-glycero-3-H-phosphonate (Manoharan et al., Tetrahedron Lett., 1995, 36, 3651-3654; Shea et al., Nucl. Acids Res., 1990, 18, 3777-3783), a polyamine or a polyethylene glycol chain (Manoharan et al., Nucleosides & Nucleotides, 1995, 14, 969-973), or adamantane acetic acid (Manoharan et al., Tetrahedron Lett., 1995, 36, 3651-3654), a palmityl moiety (Mishra et al., Biochim. Biophys. Acta, 1995, 1264, 229-237), or an octadecylamine or hexylamino-carbonyl-oxycholesterol moiety (Crooke et al., J. Pharmacol. Exp. Ther., 1996, 277, 923-937. Oligonucleotides of the invention may also be conjugated to active drug substances, for example, aspirin, warfarin, phenylbutazone, ibuprofen, suprofen, fenbufen, ketoprofen, (S)-(+)-pranoprofen, carprofen, dansylsarcosine, 2,3,5-triiodobenzoic acid, flufenarnic acid, folinic acid, a benzothiadiazide, chlorothiazide, a diazepine, indomethicin, a barbiturate, a cephalosporin, a sulfa drug, an antidiabetic, an antibacterial or an antibiotic. Oligonucleotide-drug conjugates and their preparation are described in U.S. patent application Ser. No. 09/334,130 (filed Jun. 15, 1999) which is incorporated herein by reference in its entirety.
Representative United States patents that teach the preparation of such oligonucleotide conjugates include, but are not limited to, U.S. Pat. Nos. 4,828,979; 4,948,882; 5,218,105; 5,525,465; 5,541,313; 5,545,730; 5,552,538; 5,578,717, 5,580,731; 5,580,731; 5,591,584; 5,109,124; 5,118,802; 5,138,045; 5,414,077; 5,486,603; 5,512,439; 5,578,718; 5,608,046; 4,587,044; 4,605,735; 4,667,025; 4,762,779; 4,789,737; 4,824,941; 4,835,263; 4,876,335; 4,904,582; 4,958,013; 5,082,830; 5,112,963; 5,214,136; 5,245,022; 5,254,469; 5,258,506; 5,262,536; 5,272,250; 5,292,873; 5,317,098; 5,371,241, 5,391,723; 5,416,203, 5,451,463; 5,510,475; 5,512,667; 5,514,785; 5,565,552; 5,567,810; 5,574,142; 5,585,481; 5,587,371; 5,595,726; 5,597,696; 5,599,923; 5,599,928 and 5,688,941, each of which is herein incorporated by reference.
It is not necessary for all positions in a given compound to be uniformly modified, and in fact more than one of the aforementioned modifications may be incorporated in a single compound or even at a single nucleoside within an oligonucleotide. The present invention also includes antisense compounds which are chimeric compounds. "Chimeric" antisense compounds or "chimeras," in the context of this invention, are antisense compounds, particularly oligonucleotides, which contain two or more chemically distinct regions, each made up of at least one monomer unit, i.e., a nucleotide in the case of an oligonucleotide compound. These oligonucleotides typically contain at least one region wherein the oligonucleotide is modified so as to confer upon the oligonucleotide increased resistance to nuclease degradation, increased cellular uptake, and/or increased binding affinity for the target nucleic acid. An additional region of the oligonucleotide may serve as a substrate for enzymes capable of cleaving RNA:DNA or RNA:RNA hybrids. By way of example, RNase H is a cellular endonuclease which cleaves the RNA strand of an RNA:DNA duplex. Activation of RNase H, therefore, results in cleavage of the RNA target, thereby greatly enhancing the efficiency of oligonucleotide inhibition of gene expression. Consequently, comparable results can often be obtained with shorter oligonucleotides when chimeric oligonucleotides are used, compared to phosphorothioate deoxyoligonucleotides hybridizing to the same target region. Cleavage of the RNA target can be routinely detected by gel electrophoresis and, if necessary, associated nucleic acid hybridization techniques known in the art.
Chimeric antisense compounds of the invention may be formed as composite structures of two or more oligonucleotides, modified oligonucleotides, oligonucleosides and/or oligonucleotide mimetics as described above. Such compounds have also been referred to in the art as hybrids or gapmers. Representative United States patents that teach the preparation of such hybrid structures include, but are not limited to, U.S. Pat. Nos. 5,013,830; 5,149,797; 5,220,007; 5,256,775; 5,366,878; 5,403,711; 5,491,133; 5,565,350; 5,623,065; 5,652,355; 5,652,356; and 5,700,922, each of which is herein incorporated by reference in its entirety.
The antisense compounds used in accordance with this invention may be conveniently and routinely made through the well-known technique of solid phase synthesis. Equipment for such synthesis is sold by several vendors including, for example, Applied Biosystems (Foster City, Calif.). Any other means for such synthesis known in the art may additionally or alternatively be employed. It is well known to use similar techniques to prepare oligonucleotides such as the phosphorothioates and alkylated derivatives.
The antisense compounds of the invention encompass any pharmaceutically acceptable salts, esters, or salts of such esters, or any other compound which, upon administration to an animal including a human, is capable of providing (directly or indirectly) the biologically active metabolite or residue thereof. Accordingly, for example, the disclosure is also drawn to prodrugs and pharmaceutically acceptable salts of the compounds of the invention, pharmaceutically acceptable salts of such prodrugs, and other bioequivalents.
The term "prodrug" indicates a therapeutic agent that is prepared in an inactive form that is converted to an active form (i.e., drug) within the body or cells thereof by the action of endogenous enzymes or other chemicals and/or conditions. In particular, prodrug versions of the oligonucleotides of the invention are prepared as SATE [(S-acetyl-2-thioethyl)phosphate] derivatives according to the methods disclosed in WO 93/24510 to Gosselin et al., published Dec. 9, 1993 or in WO 94/26764 and U.S. Pat. No. 5,770,713 to Imbach et al.
The term "pharmaceutically acceptable salts" refers to physiologically and pharmaceutically acceptable salts of the compounds of the invention: i.e., salts that retain the desired biological activity of the parent compound and do not impart undesired toxicological effects thereto.
The antisense compounds of the present invention can be utilized for diagnostics, therapeutics, prophylaxis and as research reagents and kits. For therapeutic use, an animal, preferably a human, suspected of having a disease or disorder which can be treated by modulating the expression of a protein is treated by administering antisense oligonucleotides in accordance with this invention. The specificity and sensitivity of antisense is particularly useful in therapeutic applications and antisense oligonucleotides have been employed as therapeutic moieties in the treatment of disease states in animals and man. Antisense oligonucleotide drugs, including ribozymes, have been safely and effectively administered to humans and numerous clinical trials are presently underway. It is thus established that oligonucleotides can be useful therapeutic modalities that can be configured to be useful in treatment regimes for treatment of cells, tissues and animals, especially humans. The compounds of the invention can be utilized in pharmaceutical compositions by adding an effective amount of an antisense oligonucleotide to a suitable pharmaceutically acceptable diluent or carrier. Use of the antisense oligonucleotides and methods of the invention may also be useful prophylactically, e.g., to prevent or delay infection, inflammation or tumor formation, for example.
The antisense oligonucleotides of the invention are useful for research and diagnostics, because these compounds hybridize to nucleic acids encoding a protein involved in a disease state, enabling sandwich and other assays to easily be constructed to exploit this fact. Hybridization of the antisense oligonucleotides of the invention with a nucleic acid encoding a protein involved in a disease state can be detected by means known in the art. Such means may include conjugation of an enzyme to the oligonucleotide, radiolabelling of the oligonucleotide or any other suitable detection means. Kits using such detection means for detecting the level of a protein involved in a disease state in a sample may also be prepared.
It is believed that the present invention will be used most widely with antisense oligonucleotides whose bioavailability and/or absorption properties can be enhanced by use of the permeation enhancer of the present invention. It is believed also that the present invention can be used to a particularly good effect by combining the permeation enhancer of the present invention with an antisense oligonucleotide that is ingested orally and absorbed relatively poorly in the gastrointestinal tract ("GIT").
The antisense oligonucleotide can be in any suitable form, for example, in crystalline or amorphous form and in solid, liquid, or gel form, for example, in the form of nano particles and micro particles or in larger particle-size form. In addition, the antisense oligonucleotide can be present in the composition in a time-release form.
The composition of the present invention comprises a pharmaceutically effective amount of the antisense oligonucleotide, that is, an amount that is effective in achieving the desired prophylactic, therapeutic or diagnostic effect in the patient. It should be appreciated that the amount of antisense oligonucleotide comprising the composition will depend on various factors, including, for example, the particular antisense oligonucleotide used, the nature of the condition to be treated, and the nature of the patient.
Similarly, the enhancer compound contained in the composition of the present invention is present in an amount that is effective in increasing the bioavailability and/or absorption properties of the antisense oligonucleotide. The amount of enhancer in the composition will depend on various factors, including, for example, the presence of other enhancer compounds, the particular antisense oligonucleotide(s) used, the amount of antisense oligonucleotide(s) employed, the dosage form selected, the nature of the dosage form, the nature of the enhancer, the particular enhancer compound used, the optical purity of the enhancer compound used, that is whether it is used in the form of a pure isomer or as a partially or completely racemic mixture. It is believed that, for most applications, the composition will comprise an antisense oligonucleotide: enhancer ratio of about 1:99 to about 99:1. Typically, the ratio will be between about 1:20 and about 20:1. This ratio range is given for guideline purposes, with the understanding that ratios of antisense oligonucleotide to enhancer outside of this range may be used depending on the various factors mentioned above.
The composition of the present invention comprises optionally a vehicle, the nature of which will depend on the form of the composition. The composition can be used in any suitable form, for example, in the form of a granulate, solid, semi-solid, solution, suspension, tablet, capsule, inhalant, suppository, or enema. The tablets and capsules can be in the form, for example, of delayed release, sustained release, or immediate release systems. It is believed that the composition of the present invention will be used most widely in solid or semi-solid oral dosage form.
The term "vehicle" is used broadly to include various types of pharmaceutically acceptable ingredients that can comprise the composition other than the drug and enhancer constituents of the composition. Examples of vehicles include fillers, diluents, excipients and materials, which have an effect on the release properties of the antisense oligonucleotide or on the enhancer compound(s), that is, control-release materials. Examples of fillers and diluents include lactose, mannitol, dextrose, vegetable oils, glycerides, and microcrystalline cellulose. Examples of excipients include phosphate and citrate salts, magnesium stearate, silica, and binders such as hydroxypropyl methylcellulose, polyvinylpyrrolidone, and starch. Examples of control-release materials include enteric polymers, hydroxypropyl methylcellulose.
The amount of the various classes of constituents that comprise the carrier can be selected by the user to achieve the desired effects.
The examples below are illustrative of the present invention and compare the present invention to prior art compositions.
Antisense oligonucleotides were synthesized by solid phase organic synthesis using appropriately protected synthons. Reversed phase chromatography is used to purify the antisense oligonucleotide, which is then deprotected and lyophilized.
An example of a formulation containing an enhancer of the present development and an antisense oligonucleotide is a composition comprising sodium 2-n-octyl-dodecanoate, sodium caprate and an antisense oligonucleotide, which targets TNFα. This antisense oligonucleotide is a 2′-O-(2-methoxyethyl) modified phosphorothioate oligonucleotide containing a 10-base 2′ deoxy gap, also referred to as a 5-10-5 MOE gapmer, with 2′ MOE modification of only the five nucleotides at the 3′ and 5′ termini of the oligonucleotide wherein each of the 19 inter-nucleotide linkages is an O,O-linked phosphorothioate. In addition, all cytosines are modified to 5-methylcytosines. The 2′ MOE modification makes an oligonucleotide more resistant to nuclease degradation, thereby improving both its RNA binding affinity and increasing its half life. This antisense oligonucleotide targets human TNF-α and can be used to treat inflammatory disorders, such as rheumatoid arthritis. The antisense oligonucleotide has a sequence of:
An antisense oligonucleotide treatment composition will be prepared comprising sodium 2-n-octyl-dodecanoate, sodium caprate, and an antisense oligonucleotide which targets human c-raf kinase which can be used to treat hyperproliferation disorders, such as various forms of cancer. The antisense oligonucleotide has a sequence of:
Each of the inter-nucleotide linkages is an O,O-linked phosphorothioate.
An antisense oligonucleotide treatment composition will be prepared comprising sodium 2-n-octyl-dodecanoate, sodium caprate, and an antisense oligonucleotide which targets human papillomavirus which can be used to treat warts including, for example, genital warts. The antisense oligonucleotide has a sequence of:
Each of the inter-nucleotide linkages is an O,O-linked phosphorothioate.
An antisense oligonucleotide treatment composition will be prepared comprising sodium 2-n-octyl-dodecanoate, sodium caprate and an antisense oligonucleotide which targets the intercellular adhesion molecule-1(ICAM-1) and can be used to treat inflammatory disorders, for example, inflammatory bowel disorders, psoriasis and rheumatoid arthritis. The antisense oligonucleotide has a sequence of:
Each of the inter-nucleotide linkages is an O,O-linked phosphorothioate.
Compositions comprising sodium caprate and an antisense compound with and without an enhancer compound of the present development, sodium 2-n-octyl-dodecanoate, were administered to animals to demonstrate the enhanced bioavailability of macromolecular compounds for example, oligo- and polynucleotides, afforded by the enhancer compounds of the present development. The ratio of enhancer and antisense compounds in the compositions is shown in Table 6.
Antisense oligonucleotides were synthesized by solid phase organic synthesis using appropriately protected synthons. Reversed phase chromatography was used to purify the antisense oligonucleotide, which was then deprotected and lyophilized.
The antisense oligonucleotide used was a 2′-O-(2-methoxyethyl) modified phosphorothioate oligonucleotide containing a 10-base 2′ deoxy gap, also referred to as a 5-10-5 MOE gapmer, with 2′ MOE modification of only the five nucleotides at the 3′ and 5′ termini of the oligonucleotide wherein each of the 19 inter-nucleotide linkages is an O,O-linked phosphorothioate. In addition, all cytosines are modified to be 5-methylcytosines. The 2′ MOE modification makes an oligonucleotide more resistant to nuclease degradation, thereby improving both its RNA binding affinity and increasing its half life. This antisense oligonucleotide targets human TNF-α to treat inflammatory disorders, such as rheumatoid arthritis. This antisense oligonculeotide has a sequence of:
The compositions were compared by administering them in solution form through a catheter to test subjects. A jejunal catheter is surgically implanted in six male rhesus monkeys (3-5 years, 3-5 Kg) under anesthesia. The catheters are attached to a subcutaneous access port to allow dosing through the port into the jejunum. The animals are allowed to recover at least 7 days prior to dosing. Animals were fasted overnight prior to dosing and fed 2 hours post-dosing. Test formulations are prepared in water and are dosed to animals as a bolus (0.5 ml/kg) in a cross-over study design with a one week wash out period between each dose. Whole blood samples are taken from the femoral vein (other than the dosing site for intravenous administration) at the following time intervals: 0 (pre-dose) 2, 5, 10, 20, 30, 45, 60, 90, 120, 180, 240 and 360 minutes for intravenous dose and at 0 (pre-dose), 5, 15, 30, 45, 60, 90, 120, 150, 180, 240, 360 and 480 minutes for intrajejunal doses. The samples are collected in EDTA-containing tubes and centrifuged in a refrigerated centrifuge (2-8� C.) to obtain plasma that is stored at -70� C. until analysis. The antisense oligonucleotide is detected by anion-exchange chromatography.
The formulations and the measurements bioavailability, Tmax and plasma peak of antisense oligonucleotide after administration of formulations are described in the chart below. The bioavailability (i.e. relative to an intravenous dose) is calculated from the areas under the curve obtained from plasma oligonucleotide concentration-time profiles.
TABLE 6 Antisense Antisense Oligonucleotide Oligonucleotide (10 mg/kg) (10 mg/kg) Sodium 2-n-octyl-dodecanoate Sodium caprate (15 mg/kg) + Sodium PK parameters (50 mg/kg) caprate (35 mg/kg) Peak 2.7 � 1.5 8.7 � 3.8* plasma (g/ml) Tmax (min) 19 � 12 30 � 9 AUC 127 � 8.7 451 � 224* (g � min/ml) % 3.0 � 2.1 10.8 � 5.4* Bioavailability Results of above table are expressed as mean � SD (n = 6), AUC = area under concentration-time curve, Tmax = time to reach peak plasma concentration; *p < 0.05.
The antisense oligonucleotide has poor permeability when administered to monkeys orally or intra-intestinally without any permeation enhancer systems. This bioavailability is significantly improved when the drug is dosed with a permeation enhancer. The highest bioavailability is observed with compositions including the permeation enhancer sodium 2-n-octyl-dodecanoate, in which bioavailability ranged from 5.2% to 18.2%. The enhancement of bioavailability with the branched chain enhancer compound relative to the straight chain sodium caprate alone is not only related to the increase in plasma peak but also to a significant increase in the overall area under the curve. The bioavailability achieved with compositions containing only the straight chain carboxylic acid salt, sodium caprate, ranged from 1.0% to 6.2%, a significantly reduced permeation enhancing effect.
|Cited Patent
|Filing date
|Publication date
|Feb 22, 1983
|Sep 4, 1984
|Eli Lilly And Company
|Contraceptive device
|Oct 15, 1982
|Jun 25, 1985
|Hoffmann-La Roche Inc.
|Enteric coated oral dosage form
|May 3, 1985
|Feb 24, 1987
|Alza Corporation
|Transdermal delivery of highly ionized fat insoluble drugs
|Aug 27, 1984
|Apr 7, 1987
|Basf Aktiengesellschaft
|Increasing the enteral absorbability of heparin or heparinoids
|Jun 12, 1986
|Sep 8, 1987
|Spofa, Spojene Podniky Pro Zdravotnickou Vyrobu
|Method for treatment of endometritis in mammalian females
|Jun 17, 1987
|Dec 6, 1988
|Warner-Lambert Company
|Transdermal matrix system
|Apr 8, 1988
|Mar 6, 1990
|Cygnus Research Corporation
|Transdermal drug-delivery composition
|May 2, 1988
|Mar 20, 1990
|Schering Corporation
|Transdermal delivery of loratadine
|Apr 8, 1988
|Mar 27, 1990
|Cygnus Research Corporation
|Diffusion matrix for transdermal drug administration and transdermal drug delivery devices including same
|Jul 20, 1989
|Feb 19, 1991
|Merck & Co., Inc.
|Solubility modulated drug delivery device
|May 17, 1990
|Feb 11, 1992
|Bristol-Myers Squibb Co.
|Controlled dermal penetration enhancement using imidazoles
|Aug 15, 1989
|Feb 25, 1992
|Yu Ruey J
|Amphoteric compositions and polymeric forms of alpha hydroxyacids, and their therapeutic use
|Dec 18, 1991
|Mar 2, 1993
|Hoffmann-La Roche Inc.
|Absorption enhancement of antibiotics
|Dec 20, 1991
|Jul 20, 1993
|Cygnus Therapeutics Systems
|Vegetable oil-based skin permeation enhancer compositions, and associated methods and systems
|Sep 5, 1989
|Feb 22, 1994
|The University Of Utah
|Compositions of oral dissolvable medicaments
|Oct 4, 1991
|Dec 20, 1994
|Bristol-Myers Squibb Company
|Imidazole dermal penetration enhancers
|Mar 30, 1993
|Mar 21, 1995
|Schering Aktiengesellschaft
|Agent for transdermal administration containing ergoline derivatives
|May 2, 1992
|Feb 20, 1996
|Lts Lohmann Therapie-Systeme Gmbh & Co. Kg
|Lanoline derivatives as penetration enhancing substances
|Apr 22, 1994
|Jul 30, 1996
|Emisphere Technologies, Inc.
|Acids and acid salts and their use in delivery systems
|Apr 28, 1994
|Dec 3, 1996
|Hoffmann-La Roche Inc.
|Pharmaceutical composition for transdermal delivery
|Mar 31, 1995
|Jul 22, 1997
|Emisphere Technologies, Inc.
|Compositions for oral delivery of active agents
|Apr 20, 1995
|Sep 2, 1997
|Bertek, Inc.
|Transdermal patch incorporating a polymer film incorporated with an active agent
|Jun 16, 1994
|Feb 3, 1998
|Pharmacia & Upjohn Aktiebolag
|Pharmaceutical composition containing heparin, heparin fragments or their derivatives in combination with glycerol esters
|Apr 8, 1997
|Sep 1, 1998
|Isis Pharmaceuticals, Inc.
|Antisense oligonucleotide modulation of multidrug resistance-associated protein
|Jan 3, 1997
|Nov 10, 1998
|Theratech, Inc.
|Triacetin as a penetration enhancer for transdermal delivery of a basic drug
|Jul 23, 1996
|Nov 17, 1998
|Grasela; John C.
|Transdermal delivery of medications using a combination of penetration enhancers
|Nov 16, 1995
|Dec 29, 1998
|Toray Industries, Inc.
|Preparation for percutaneous absorption
|Nov 5, 1997
|Jan 26, 1999
|Theratech, Inc.
|Buccal delivery of glucagon-like insulinotropic peptides
|Jun 1, 1995
|Feb 2, 1999
|Hisamitsu Pharmaceutical Co., Ltd.
|Matrix patch formulation
|Oct 29, 1997
|Jun 15, 1999
|Theratech, Inc.
|Fatty acid esters of glycolic acid and its salts
|Oct 29, 1997
|Sep 14, 1999
|Theratech, Inc.
|Fatty acid esters of lactic acid salts as permeation enhancers
|Apr 3, 1997
|Nov 2, 1999
|Cedars-Sinai Medical Center
|Methods and compositions for improving digestion and absorption in the small intestine
|Dec 18, 1996
|Dec 14, 1999
|Alza Corporation
|Formulations for transdermal delivery of pergolide
|Mar 29, 1996
|Jan 4, 2000
|Pharmaceutical composition for transdermal administration
|Dec 30, 1998
|Apr 18, 2000
|Tristrata Technology, Inc.
|Additives enhancing the effect of therapeutic agents
|Feb 27, 1998
|Oct 17, 2000
|3M Innovative Properties Company
|Transdermal device for the delivery of testosterone
|Sep 28, 1999
|Nov 28, 2000
|The Procter & Gamble Company
|Article having a transferable breathable skin care composition thereon
|Aug 8, 1996
|Mar 13, 2001
|West Pharmaceutical Services Drug Delivery & Clinical Research Centre Limited
|Composition for enhanced uptake of polar drugs from the colon
|Jun 5, 1998
|Mar 20, 2001
|Alza Corporation
|Reduction of skin reactions caused by transdermal drug delivery
|Aug 12, 1999
|Jul 17, 2001
|The Dow Chemical Company
|Compositions having improved ignition resistance
|Oct 27, 1999
|Jul 24, 2001
|Anesta Corporation
|Oral transmucosal drug dosage using solid solution
|Jun 30, 1999
|Jul 31, 2001
|Lipocine Inc.
|Clear oil-containing pharmaceutical compositions
|Jun 23, 1998
|Jul 31, 2001
|Teikoku Seiyaku Co., Ltd.
|Stable aspirin-containing preparations for external use
|Mar 10, 1999
|Dec 4, 2001
|Grelan Pharmaceuticals Co., Ltd.
|Bubbling enteric coated preparations
|Dec 6, 2000
|Apr 30, 2002
|Isis Pharmaceuticals, Inc.
|Antisense modulation of damage-specific DNA binding protein 2, p48 expression
|Mar 6, 2000
|Jun 24, 2003
|Affymetrix, Inc.
|Mar 6, 2000
|Dec 20, 2001
|Fodor Stephen P.A.
|May 13, 2002
|Jan 23, 2003
|Raoof Araz A.
|Isostearic acid salts as permeation enhancers
|Mar 12, 2003
|Dec 11, 2003
|Cowsert Lex M.
|Identification of genetic targets for modulation by oligonucleotides and generation of oligonucleotides for gene modulation
|Nov 14, 2003
|Feb 8, 2007
|Anastasia Khvorova
|Functional and hyperfunctional siRNA
|Nov 21, 1989
|May 30, 1990
|F. Hoffmann-La Roche Ag
|Pharmaceutical preparations for the enhanced resorption of antibacterial compounds
|Dec 11, 1989
|Jul 4, 1990
|Riker Laboratories, Inc.
|Topical formulations and transdermal delivery systems containing 1-isobutyl-1H-imidazo[4,5-c]quinoline-4-amine
|Jan 17, 1992
|Aug 5, 1992
|ALFA WASSERMANN S.p.A.
|Pharmaceutical compositions containing orally absorbable glycosaminoglycans
|Jun 4, 1992
|Dec 9, 1992
|Teikoku Seiyaku Kabushiki Kaisha
|Physiologically active polypeptide containing pharmaceutical composition
|Jul 15, 1993
|Jan 26, 1994
|ASTA Medica Aktiengesellschaft
|Stable preparation containing azelastine hydrochloride
|Title not available
|Title not available
|Title not available
|Title not available
|Title not available
|Title not available
|May 29, 1984
|Dec 6, 1984
|Jang Choong Gook
|Dry direct compression compositions for controlled release dosage forms
|Apr 21, 1993
|Nov 11, 1993
|Leiras Oy
|Pharmaceutical preparation and process for its manufacture
|Feb 14, 1995
|Aug 24, 1995
|Abbott Laboratories
|Process for preparing fine particle pharmaceutical formulations
|Jun 13, 1995
|Dec 21, 1995
|Yissum Research Development Company Of The Hebrew University Of Jerusalem
|Controlled release oral drug delivery system
|Aug 8, 1996
|Feb 20, 1997
|Danbiosyst Uk Limited
|Composition for enhanced uptake of polar drugs from the colon
|Jul 1, 1998
|Jan 14, 1999
|Isis Pharmaceuticals, Inc.
|Compositions and methods for the delivery of oligonucleotides via the alimentary canal
|Jul 7, 1998
|Jan 21, 1999
|D-Pharm Ltd.
|Compositions and methods for reversibly increasing permeability of biomembranes
|Jul 7, 1998
|Jan 21, 1999
|D-Pharm Ltd.
|Branched chain fatty acids, their derivatives and use in the treatment of central nervous system disorders
|Mar 10, 1999
|Sep 16, 1999
|Grelan Pharmaceutical Co., Ltd.
|Bubbling enteric coated preparations
|May 20, 1999
|Nov 25, 1999
|Isis Pharmaceuticals, Inc.
|Compositions and methods for non-parenteral delivery of oligonucleotides
|Oct 18, 1999
|Apr 27, 2000
|Biotech Australia Pty. Limited
|Systems for oral delivery
|Feb 22, 2000
|Aug 31, 2000
|Elan Corporation, Plc
|Solid oral dosage form containing an enhancer
|May 13, 2002
|Nov 21, 2002
|Elan Corporation, Plc
|Isostearic acid salts as permeation enhancers
|Anderberg et al., "Sodium Caprate Elicits Dilatations in Human Intestinal Tight Junctions and Enhances Drug Absorption by the Paracellular Route", Pharmaceutical Research (1993), 10:857-864.
|Artursson, P., "Epithelial Transport of Drugs in Cell Culture. I: A model for Studying the Passive Diffusion of Drugs over Intestinal Absorbative (Caco-2) Cells", J. Pharmaceutical Studies (1990), 79: 476-482.
|Aungst, "Structure/Effect Studies of Fatty Acid Isomers as Skin Penetration Enhancers and Skin Irritants" Phamaceutical Research 6(3):244-247 (1989).
|Aungst, et al., "Enhancement of the Intestinal Absorption of Peptides and Non-peptides", J. of Controlled Release (1996), 41:19-31.
|Bennett et al, "Pulmonary Delivery of Detirelix Intratracheal Instillation and Aerosol Inhalation in the Briefly Anesthetized Dog", Pharmaceutical Research (1994), vol. 11, No. 7, 1048-1054.
|Branch et al., "A good antisense molecule is hard to find," TIBS (1998) 23:45-50.
|Brayden et al,"Heparin Absorption Across the Intestine: Effects of Sodium N-[8-(2-Hydroxybenzoyl)Amino]Caprylate in Rat in Situ Intestinal Instillations and in Caco-2 Monolayers", Pharmaceutical Research, 1997, 14(12), 1772-1779.
|Chin, Andrew "On the Preparation and Utilization of Isolated and Purified Oligonucleotides." Document purportedly located on a CD-ROM and contributed to the public collection of the Katherine R. Everett Law Library of the University of North Carolina on Mar. 14, 2002.
|Crooke et al., "Basic Principles of Antisense Therapeutics" Antisense Research and Application (1998) Chapter 1:1-50.
|Cumming et al., "In vitro evaluation of a series of sodium carboxylates as dermal penetration enhancers" International Journal of Pharmaceuticals (1994) 108(2):141-148.
|Doluisio et al, "Drug Absorption I: An in Situ Rat Gut Technique Yielding Realistic Absorption Rates", J. Pharmaceutical Studies (1969), 59:1196-1200.
|English translation of abstract of Japanese Patent Application No. JP 03 275 633, filed Dec. 6, 1991.
|English translation of abstract of Japanese Patent Application No. JP 2004529953, filed Sep. 30, 2004.
|English translation of abstract of Japanese Patent Application No. JP 59 073 600, filed Apr. 25, 1984.
|English translation of abstract of Russian Patent Application No. RU 2 068 689, filed Nov. 10, 1996.
|Gennaro, A.R., Remingtion: The Science and Practice of Pharmacy (1995), 1618.
|International Search Report from PCT/US2002/015166, dated Sep. 19, 2002.
|Lee et al, "Critical Reviews in Therapeutic Drug Carrier Systems", 1991, 8(2), 91-192.
|Lindmark et al., "Mechanism of Absorption Enhancement in Humans After Rectal Administration of Ampicillin in Suppositories Containing Sodium Caprate", Pharmaceutical Research (1997), 14:930-935.
|Muranishi, Critical Reviews in Therapeutic Drug Carrier Systems, 1990, 7(1), 1-33.
|New England BioLabs, Inc. Catalogue (1998): 121, 284.
|Oda et al, Proc. Int'l Symp. Control. Rel. Bioact. Mater. 24 (1997) 283-284.
|Reynolds et al., Rational siRNA design for RNA interference, Mar. 2004, Nature Biotechnology, vol. 22, pp. 326-330.
|Sanghvi et al., "Heterocyclic Base Modifications in Nucleic Acids and Their Applications in Antisense Oligonucleotides" Antisense Research and Applications (1993) pp. 273-288.
|Schneider et al. "Evaluation of Drug Penetration into Human Skin Ex Vivo Using Branched Fatty Acids and Propylene Glycol" International Journal of Pharmaceutics 145:187-196 (1996).
|Supplementary European Search Report for Application EP 02731781 dated Jun. 6, 2008.
|Tomita et al., "Enhancement of Colonic Drug Absorption by the Paracellular Permeation Route", Pharmaceutical Research (1988), 5:341-346.
|Yeh et al,Effect of Medium-chain Glycerides on Physiological Properties of Rabbit Intestinal Epithelium in Vitro, Pharmaceutical Research (1994), 11:1148-1154.
|U.S. Classification
|International Classification
|Cooperative Classification
|European Classification


text:
Compulsory Third Party NSW Green Slip Insurance provides protection to vehicle owners and drivers who are legally liable for personal injury caused to others involving the operation of their vehicle.
You know you can count on QBE to provide quality insurance and to be there when you need us most. So it makes sense to trust us with your Compulsory Third Party Insurance (also known as CTP Insurance or Green Slip Insurance in NSW). Insuring with QBE means you can rest assured knowing you're covered in the event of an accident involving your vehicle that causes injury to others.
At QBE, if you are over 30 and a good driver with zero demerit points, we'll give you a lower price.
Release 7_0_0_6

subset: commoncrawl


text:
Meal Type
Featured Videos
Featured Content
Featured Brand Sites
Product By Category
Tools & Info
Cooking Tips
Healthy Living
Your Kids
food&family Magazine
Tap or click steps to mark as complete
Substitute Lime Jell-O Gelatin on March 17th for "Saint Patrick's Day" and it is miraculously transformed into Larry's Famous Irish Key Lime Pie.
Also, you can substitute sugar free JELL-O Products, 1 tsp. almond extract in place of amaretto liquor and real whipping cream in place of Cool Whip for diabetics!
Larry's Key Lime Pie is scrumptious, easy to make and uses almost all Kraft products. It is a big hit among my family and friends in the "First State". "Enjoy" ...ljjd...
This mainly tastes like a lemon pie slightly flavored with key lime. The amaretto seeps into the crust. There is a ton of extra topping that does not fit in a 9" pie crust. Did not find this recipe comparable to any key lime pie that I've tasted (restaurant as well as frozen).
Believe me when I say that I've tasted many variations of keylime pie and this one, by far, surpasses all of them. I had this recipe at the last dinner party I attended and couldn't stop eating!!
A feastable for entertaining. The perfect blend of sweet and sour (tart) for the taste buds. Very creamy texture, melts in your mouth. The lime green color would compliment any table setting, any time of year. Two-thumbs up!


text:
David WainShared publicly -
Add a comment...
Why are there 5,280 feet to a mile?Cool Quiz! Trivia, Quizzes, Puzzles, ...
The measurement known as a mile is a vestige of the Holy Roman Empire's rule over Britain. At this time, the Romans had a measurement known
Sierra/Affinity Selling Dennis Iliadis-Directed 'Plus One' At Cannes
Sierra/Affinity will handle international sales at Cannes for Plus One, the Dennis liadis-directed thriller. Script is by Bill Gullo based o


text:
Admission: Free
Meeting Place: Visitor Center
Be inspired by the insights of conservationist, Aldo Leopold. Local educators, environmentalists, and land managers will be reading excerpts from Leopold's very moving Sand County Almanac.
Explore Hobbs State Park-Conservation Area with our helpful maps and brochures! Just click on an icon to view, or right-click on your mouse to save a
copy to your computer.


text:
That's an easy fix. We'll point you in the right direction.
…for now. We'll show you where to dive in.
Collect your choice of gallery quality Giclée, or fine art prints custom trimmed by hand in a variety of sizes with a white border for framing.
The olymPICS serie, my tribute to 2012 London Olympic Games. Have fun.
LogIn or register to comment!
Or, sign-in with your Facebook account:


text:
NCI Dictionary of Cancer Terms
The NCI Dictionary of Cancer Terms features 7,926 terms related to cancer and medicine.
Browse the dictionary by selecting a letter of the alphabet or by entering a cancer-related word or phrase in the search box.
- epoetin beta
- listen (ee-POH-eh-tin BAY-tuh)
- A substance that is made in the laboratory and stimulates the bone marrow to make red blood cells. It is a type of antianemic and a type of recombinant human erythropoietin.


text:
For a few years now I have been using slackware, so decide to move on to Solaris. I have recently purchased a new computer and installed solaris 10 on it. Now I am working with solaris, but I have some issues in that.
1) Package Management in Solaris - Solaris uses pkgadd to install the packages. I just downloaded the packages from the repository, unzipped and installed. Are there any better way to do this task? How to view all the packages that I have installed on my system? How can i remove and upgrade a package.
2) How can I sort my PATH properly? I think it is currently showing to /usr/sbin. I know there more than this to add. wget works when I am adding some a path. But I think there is some thing more and how can I make this permanent?
3) I always like bash but the default shell is /bin/sh. Is there a way to make the bash shell default? Where to set the bashrc file?


text:
Buying Guide for Inline Skates
Chums & Quiksilver Accessories
Showing 1 - 3 items
Protect your dome in the Bushmaster Hat from Quiksilver. This wide brimmed hat features an adjustable chin strap for customization. Mountain wave and front embroidery brings a touch of style while keeping your face and neck out of the sun's harmful ray... Read More
{boxId:"compare5baa078daa62f050e85538485e", id:"100015P"}
Reg. $129.95
Upgrade your fall and winter wardrobe with the Quiksilver Into The Wild Zip-Up Fleece Hoodie. Made of a polyester/wool blend with a high-pile fleece interior, this hoodie is soft and warm for all your cold weather activities. It features a full zip-up ... Read More
{boxId:"compare5b57d76a1dbce06d45ea623cd9", id:"426892P"}
Whether you are heading to the beach, school, or on vacation the Quiksilver New Wave Backpack better be on your shoulders with you. This sleek backpack comes with a standard laptop sleeve within the main compartment. Adjustable shoulder and sternum s... Read More
{boxId:"comparebe549b7787260b724b093d4553", id:"378288P"}


text:
Metallic cable ties are great choices when issues such as strength and temperature resistance are paramount. Able to withstand more temperature extremes than nylon ties, aluminum and steel metal ties are suited for harsh environments. Coated metal ties are also available for food processing or manufacturing environments where cable ties must be easily detectable, and also for industries susceptible to galvanic attack (corrosion due to proximity of two dissimilar metals).
HomeCable ManagementCable TiesMetal Cable Ties
Metal Cable Ties
Stainless Steel see article
What can make this page better?
We do everything we can think of to provide you with the product specs, images and ordering info you need, but if we're missing something or still have room to improve, please let us know. Your comments, suggestions and questions are the best tools we have for serving you better!


text:
Gift vouchers
Sign in / Register
Get our newsletter
Please wait...
Sign up to our newsletter to receive news and offers straight to your inbox.
Newsletter signup
HomeOur HotelsMacdonald Elmers Court Hotel & ResortFunction RoomsThe Ballroom
Macdonald Elmers Court Hotel & ResortSouth Baddesley RoadHampshireSO41 5ZBTel 0344 879 9060International +44 1590 676011
The Ballroom is located in the heart of our stately Victorian
manor house and is capable of hosting conferences, training
sessions and functions for up to 150 people. This spacious room
boasts a lofty sculpted ceiling and a large fireplace along with
easy access to the Queen Mary lawn terrace. A truly majestic
venue for any function.
The Ballroom boasts a lofty sculpted ceiling and a large
fireplace along with access to the Queen Mary lawn terrace through
magnificent patio doors. Truly a majestic venue for any
Click to see the larger floor plan
Morbi nulla sapien, molestie sed imperdiet eget, mollis sed lacus.
on application
Get news & offers straight to your inbox
Stay connected with us:
Copyright © Macdonald Hotels 2016


text: Girls Brushed Cotton Pyjamas: More Colours by PJ Pan £36$69.35€46.33$52.06 In stock £6.95$13.38€8.94$10.05 delivery to United States Receive this item 5-10 working days from dispatch International delivery available sizesize (required)2-3yrs3-4yrs 5-6yrs (+ £2)7-8yrs SOLD OUT (+ £4)9-10yrs SOLD OUT (+ £6)size (required)2-3yrs3-4yrs 5-6yrs (+ $3.85)7-8yrs SOLD OUT (+ $7.70)9-10yrs SOLD OUT (+ $11.55)size (required)2-3yrs3-4yrs 5-6yrs (+ €2.57)7-8yrs SOLD OUT (+ €5.14)9-10yrs SOLD OUT (+ €7.72)size (required)2-3yrs3-4yrs 5-6yrs (+ $2.89)7-8yrs SOLD OUT (+ $5.78)9-10yrs SOLD OUT (+ $8.67) colourcolour (required)Pink & taupePink & cream - SOLD OUTcolour (required)Pink & taupePink & cream - SOLD OUTcolour (required)Pink & taupePink & cream - SOLD OUTcolour (required)Pink & taupePink & cream - SOLD OUT quantity by PJ Pan Location: Perthshire, GB read seller's profile see seller's complete range more items from this seller Girls Flowery Blue Striped Pyjamas 2-10yrs by PJ Pan £36$69.35€46.33$52.06 Girls Pink Flower Bud Pyjamas 2-10yrs by PJ Pan £36$69.35€46.33$52.06 Check Pyjamas With Mother Of Pearl Buttons by PJ Pan £79$152.18€101.68$114.25 Boys Brushed Cotton PJs: More Colours by PJ Pan £36$69.35€46.33$52.06 Women's Red And Purple Tartan Pj Bottoms by PJ Pan £42$80.90€54.06$60.74 Long & Reg Leg Luxury White Cotton Pyjamas by PJ Pan £95$183€122.28$137.39 view all you may also like PRODUCT DETAILS CUSTOMER REVIEWS DELIVERY RETURNS Made in Britain ask seller a question save for later Children's brushed cotton pyjamas in two pretty pink checks. Pink & taupe or pink and cream. Finished with pretty piping and real shell buttons. Practical trousers with elasticated waist and functional drawstring. 100% finest quality cotton. All patterns are woven in, not printed, making these pyjamas extra special. The sizing for our children's pyjamas and pyjama bottoms are based on dual sizes, so they are designed to fit the age at the upper end of the size. The leg lengths are generous but can of course be taken up if needed. All trousers have a functional drawstring so they can be tightened if the child has a small waist. Please refer to the sizing chart below for more details. age height waist chests outside leg of trousers 2-3 years 98cm 51cm 54cm 52cm 3-4 years 104cm 52cm 56cm 58cm SOLD OUT IN PINK & CREAM and PINK & TAUPE 5-6 years 116cm 55cm 60cm 66cm SOLD OUT IN PINK & CREAM 7-8 years 128cm 59cm 65cm 74cm SOLD OUT 9-10 years 140cm 63cm 71cm 82cm SOLD OUT IN PINK & CREAM Matching adults pyjamas available so why not buying matching mother/daughter pjs! made from: Finest quality cotton with a gently brushed finish. product code: 111051 1 customer review read about our product rating system ratings guide trusted independent customer feedbackforum excellent bad good poor This product is dispatched to you by PJ Pan. MAINLAND UK order now and receive this item by price Standard Delivery Thursday 2 June £1.75$3.37€2.25$2.53 Tracked Next Day 1pm Delivery Wednesday 1 June £8.70$16.75€11.19$12.58 NON-MAINLAND UK estimated delivery price Highlands & Islands of Scotland 2-5 working daysfrom dispatch £1.75$3.37€2.25$2.53 Northern Ireland 2-5 working daysfrom dispatch £1.75$3.37€2.25$2.53 Other UK Islands 2-5 working daysfrom dispatch £1.75$3.37€2.25$2.53 INTERNATIONAL DELIVERY estimated delivery price Western Europe 2-5 working daysfrom dispatch £5.00$9.63€6.43$7.23 Rest of Europe 5-10 working daysfrom dispatch £5.00$9.63€6.43$7.23 USA & Canada 5-10 working daysfrom dispatch £6.95$13.38€8.94$10.05 Asia & Australasia 5-10 working daysfrom dispatch £7.25$13.96€9.33$10.48 Rest of the world 5-14 working daysfrom dispatch £7.25$13.96€9.33$10.48 You have 28 days, from receipt of cancellable goods, to notify the seller if you wish to cancel your order or exchange an item. Please note: goods that are personalised, bespoke or made-to-order to your specific requirements, perishable products and personal items sold with a hygiene seal (cosmetics, underwear) in instances where the seal is broken are non-refundable, unless faulty. Read more about our returns policy.Should you choose to return or exchange your order you will need to deliver the item(s) to the UK, where this seller is based. PJ Pan's return policy Please see notonthehighstreet.com's returns policy.


text:
Currency Displayed in
Torah Sand Art No sand 1 Dozen, Jewish Sand Art Boards, Not Including Sand, Jewish Sand Art - 12 Boards, 5" x 7" . A great activity for Jewish Children. Just peel off the sections and create a beautiful sand picture on the self-adhesive board using colored sand. Contains: 12 Self-adhesive "peel-off" boards: 12 Boards 5" x 7" .
Shop with confidence! At Benny's we stand behind the quality of our products. If a product you have purchased at Benny's is not of the expected quality - you may return it for a full refund of the purchase price.
This product hasn't received any reviews yet. Be the first to review this product!
All prices are in USD.


text:
Some subtle lessons that all cyclists and drivers need to know.
Shut Up Already
7 / 12
Car crashes linked to cell-phone use have led 20 states to ban driver texting, and six currently require hands-free devices for calls. But even with a handsfree device, driving and talking on the phone makes you dangerous to everyone on the road. In one study, psychologists at the Center for Cognitive Brain Imaging at Carnegie Mellon University, in Pittsburgh, had subjects "drive" simulators while responding to spoken questions. Subjects strayed from their lanes, an obvious hazard to cyclists, and their brains (scanned by a magnetic-resonance imaging machine) showed a 37 percent drop in activity in the parietal lobe, the region tied to driving.
Copyright © 2016 Rodale Inc.


text:
LOUISBURG - Pattie Byrd Roberts Cash, of Louisburg, went to be with her blessed Lord on May 13, 2009 at her home. She was the eldest of seven children of Charlie Hinton Roberts, Sr. and Annie Byrd Perry Roberts. She was a devoted Christian wife, mother, grandmother and a good friend to all who knew her.
She faithfully worked with her husband on the farm and on the tobacco markets from Florida to Kentucky. She was a gardener, a seamstress, a quilter, a Rook player and the best fried chicken and chocolate cake cook ever.
In addition to her parents, Pattie was preceded in death by her husband, Richard H. Cash, Sr.; siblings, Mary Edna Bridges, Thelma Celestia Hall, Charlie Hinton Roberts, Jr., Ruth Lee Cash Boykin and grandson-in-law, Thomas Wayne Cooper.
She is survived by her son, Richard H. Cash, Jr. and his wife, Patsy Jones Cash; grandchildren, LuAnne Cash Cooper and Richard H. Cash, III and wife, Kelly; great-grandson, Richard H. Cash, IV. She is also survived by her sister, Linda Mae Wiggins; brother, Wiley Marvin Roberts; sister-in-law, Mabel Cash Roberts; and by numerous nieces and nephews.
The family is especially thankful to her caregiver, Alice Eaton. Alice's loving kindness and devotion in service will always be remembered.
Funeral services will be held at 2 o'clock Sunday afternoon, May 17, 2009 at Flat Rock Baptist Church with the Rev. Gary McNair officiating. The family will receive friends in the Fellowship Hall following the entombment service.
Flowers are appreciated or memorials may be made to Flat Rock Baptist Church for the "Lottie Moon Mission Fund" at 1589 Flat Rock Church Road, Louisburg, NC 27549.
A service of Bright Funeral Home & Cremation Center. (919-556-5811)
Paid Obituary


text:
The New York Jets have signed a pair of veteran offensive linemen for depth, agreeing to deals with Ray Willis and Stephon Heyer, according to the Sports Business Journal.
Willis played for Seattle from 2005-09 and also spent time with the New Orleans Saints last season.Washington Redskins and spent last season with the Oakland Raiders.
Follow me on Twitter @TitanInsider247 and @terrymc13
Terry McCormick covers the Titans for TitanInsider.comFollow @footballpost on Twitter for the latest news
- New York Jets
- Stephon Heyer
- New Orleans Saints
- Ray Willis
- Oakland Raiders
- Washington Redskins


text:
Winter Wonderland: How to Make 8 Snowflakes, Snow Crafts, and Snow Projects
Bonus: Get our newsletter & special offers for free. We will not share or sell your email address. View our Privacy Policy
Felt Christmas Tree Advent Calendar
By: Rach H from Family Ever After
We are adding the project to your Christmas Projects.
The project was added to your Christmas Projects.
Click here to view your Christmas Projects.
If you want a Pottery Barn decoration without the Pottery Barn price, then you should make the Felt Christmas Tree Advent Calendar. This is a great sewing project for the Christmas season. You only need a few basic materials to create this DIY advent calendar, which makes it very budget-friendly. Hang it on the wall in your kitchen or family room. Your kids will delight in taking treats or completing activities from each pocket during the month of December.
Estimated Cost: $11-$20
Time to complete: Weekend project
Main Material: Felt
Tags / Related Topics
Your Recently Viewed Projects
Images from other crafters
Love these projects? Get MORE delivered to your Inbox – FREE Click Here!
What's Hot
- Simple Houses DIY Advent Calendar
- DIY Mittens Homemade Advent Calendar
- Origami Box Christmas Tree Advent Calendar
- Advent Calendar Village
- 28 Fantastic Advent Calendars to Make
- Secret Doors Advent Calendar
- Printable Advent Calendar and Activities
- Recycled Newspaper Advent Calendar
- Snowing Presents Advent Calendar
- Christmas Ornament Advent Countdown Calender
Something worth saving?
- SAVE all your favorite projects
- ADD personal notes
- QUICKLY reference your projects
Free eBooks
- 11 Christmas Crafts for Kids to Create
- 11 Christmas Gift Ideas: Handmade Scarves, Hats and More
- 6 Adorable Homemade Christmas Crafts for Summer
- 7 Easy Homemade Christmas Ornaments for Kids
- 7 Thrifty Christmas Craft Ideas
- A Very Homemade Christmas: 13 Craft Ideas and Breakfast Casserole Recipes for the Family
- How to Make an Angel for Christmas: 7 Angel Crafts
- How to Make Ornaments: 10 Christmas Ornaments to Make
- How to Make Wreaths: 15 DIY Wreaths for Christmas
- Winter Wonderland: How to Make 8 Snowflakes, Snow Crafts, and Snow Projects
Our Newest Projects & Articles
- Pine Cone Christmas Tree Decorations
- 24 Paper Christmas Decorations and Other Christmas Paper Crafts
- Scrubby Snowman Craft
- Retro Ornament Crochet Scrubbies
- Gingerbread Family Crochet Christmas Ornaments
- Waiting for Santa DIY Stockings
- Vintage Clay Pot Snowman DIY Ornaments
- Baby Snowman Clay Pot Ornament
- Sakura Pen Collection Review
- Nutcracker Toilet Paper Roll Craft


text:
Discussion in 'PlanetSide 2 Gameplay Discussion' started by FeistyAsItIs, Nov 24, 2012.
I have him as a friend in the game but how do i invite him to my game or join his?
You have to have a character on the same server, same faction, make sure neither of you are already in a squad and then type /Squad invite (friends name), and then the squad leader has to invite everyone else via squad invite.
There's other ways of doing this, add him to friends, or creat an outfit together and list the squad, but this is the more direct way.
How do you invite to squad outside of a game?
What do you mean by outside of game?
Not sure if troll ...
seems like troll
I'm hoping this is a troll. People can't be this stupid surely
....Search your feelings....
like where u choose ur character and press play
you have to be in game to invite them to squad, this isnt COD.
although... it feels like it sometimes
Sir if you are not a troll please can you do society one favour?
Please, don't breed.
i invited to squad but how do i invite to game
bump pls helpl
You do not invite them to game. There are PERSISTENT servers. This is not CoD/BF where you join a specific Game Server. Planetside 2 Servers host thousands of players at once. So you join ONE server, and that it. Have you and your friend select the same Server during Character Creation and that is all you need to do. Then click play, and decide on a place to meet. Warp-Gate is best.
There is no "game". the "game" is ongoing and never ends. There are no rounds, matches, or restarts. To invite a friend to play with you, you must first make sure that the characters that you are playing are in the same faction (vanu, NC, or TR), as well as in the same server (you will need to communicate this outside of the game via phone, or person). once you have established that both of you are on the same team, and in the same server you will hit esc. Go to the social tab at the bottom, and then find the friends tab on the left. Send him a friend request and wait for him to accept it. Once your there, stay in the social tab, under the "friends" category, and you will see his name. on the right side of his name you will see an icon that looks like this >>. Click on it and a menu will appear. In that menu, you will see a tab for "invite to squad". click on it and the invite will be send. He then must accept it and viola! you are in the same squad. After that, there is no special "squad spawn" or anything like that. The only thing that the squad does is give you the ability to use in game voip in a squad only, his name will be green, and you will be given extra points for helping him out. Aside from that, you will need to communicate and figure out where to spawn, and where to attack in order to stay together.
If he was already in a squad your invite will not go through. All members being invited to a squad must first leave any squad that they are in. I hope this helps. Dont listen to the asshats who bash you for having a lack of knowledge. We all need help some times. If you ARE a troll, then i hate you for taking advantage of my niceness.
I'm going to try my best to explain
First make sure you're in the same Faction, and on the same server.
After you've invited him to your squad, at spawn find the terminal that has a world globe on it.
This will allow you to travel to three different maps on your server
Look over these maps and your friend should be visible on one of them as a little circle with a number in it, just go to the map hes in and seek eachother out.
Separate names with a comma.


text:
The Leading eBooks Store Online
3,508,729 members ⚫ 2,065,349 ebooks
New to eBooks.com?Learn more
- Bestsellers - This Week
- Foreign Language Study
- Pets
- Bestsellers - Last 6 months
- Games
- Philosophy
- Archaeology
- Gardening
- Photography
- Architecture
- Graphic Books
- Poetry
- Art
- Health & Fitness
- Political Science
- Biography & Autobiography
- History
- Psychology & Psychiatry
- Body Mind & Spirit
- House & Home
- Reference
- Business & Economics
- Humor
- Religion
- Children's & Young Adult Fiction
- Juvenile Nonfiction
- Romance
- Computers
- Language Arts & Disciplines
- Science
- Crafts & Hobbies
- Law
- Science Fiction
- Current Events
- Literary Collections
- Self-Help
- Drama
- Literary Criticism
- Sex
- Education
- Literary Fiction
- Social Science
- The Environment
- Mathematics
- Sports & Recreation
- Family & Relationships
- Media
- Study Aids
- Fantasy
- Medical
- Technology
- Fiction
- Music
- Transportation
- Folklore & Mythology
- Nature
- Travel
- Food and Wine
- Performing Arts
- True Crime
- Foreign Language Books
Most popular at the top
The Littlest VikingRHCP 2009; US$ 8.45
When Amber, the littlest Viking, set out from Scandinavia to seek her fortune she must have got lost on her way! Now she's in Pegwell Bay with no one but her pet squirrel for company. When Katie, Gary and Joshua find her stranded on the beach, they decide to look after her. Now there's a Viking living in their garden! Having a Viking in the family... more...
Hitler's CanaryRoaring Brook Press 2007; US$ 10.99
"My brother stood up so quickly he almost knocked Mama over. 'Why aren't you doing something? Do you know what the British are calling us? Hitler's canary! I've heard it on the radio, on the BBC. They say he has us in a cage and we just sit and sing any tune he wants.'" Bamse's family are theater people. They don't get involved in politics. "it had... more...
A Slice of the MoonRHCP 2015; US$ 14.09
Because of the potato me and my family left our home and travelled 6,000 miles to find a new life . . . Slim Hannigan and her family are poor but happy. Theirs is a life filled with love and laughter - and a pet pig called Hamlet. But things change overnight, and suddenly they find themselves facing hunger and danger like they have never known... more...
Peas & QueuesProfile Books 2013; US$ 6.66
How do you get rid of unwanted guests? What do you do if there's a racket in the quiet carriage? How should you eat peas, and behave in queues? How to behave, like how to punctuate, is an aspect of life that many are no longer taught - and getting it wrong is the stuff of comedy at best and humiliation at worst. Thankfully, Sandi Toksvig has come... more...
- 1
- Page


text:
No More Tears ... Sold by graemebWatch
©2011-2016 graemeb
Beautiful work!
Another great painting love the background.
beautiful facial tones, the hair looks so intricate!
As beautifully executed as it is intriguing
Thanks Olga, I was just reading your journal, hope all is OK. You should paint with your new wisdom.
amazing piece of art
very nice!!
Congratulations your work has received an AUS-ART Daily Deviation !!!!!!!!!!!!
Feel free to add this AUS-ART Daily Deviation stamp to your artists comments/description in acknowledgement of your award and achievement :thumb258352612:
Your work will be featured on the group Front page, in a Monthly article and a linkie will be featured on the group FB page
WOW every single piece is more stunning than the last
That's what I like to hear, thanks. To bad you didn't see some of these when you were down. Tears and Lace is in the gallery.
Thanks Domi, my exhibition is getting close and I need the exposure.
congratulations once again on this powerful work!
I love the detail, the composition and the color tone
awesome work
awesome work
Well done!
I love how the makeup looks very real, the character is beautiful. The line of the hand from the pinky down looks a little weak - but the face is just gorgeous.
Thanks, I rarly put a finished painting on here that way if someone pinches it there is a way of telling. The hand still needs a glazing and a few things.
Love it!
omg you're gifted. this is so beautiful.


text:
Our Vision: To increase the number of women of color in the digital space by empowering girls of color ages 7 to 17 to become innovators in STEM fields, leaders in their communities, and builders of their own futures through exposure to computer science and technology.
Your donation will help support our programs and workshops across the country.
Black Girls CODE is a proud member of the American Express #PassionProject!
We're GROWING! Join a BGC Core Team + help us train the next gen of tech leaders!
At Black Girls CODE it's our volunteers who make the engine hum; they are the foundation of the great programs that we host around the country and even the world! They make it all happen. They are the secret sauce to our story.
We are looking for a few good sisters and brothers to join these growing teams of #BGCGladiators as we expand our existing chapters and launch new ones in cities such as (Dallas, Miami, Los Angeles, Chicago, Detroit, Atlanta, Memphis, DC, Raleigh-Durham, New York) and more! If you're motivated to change the lives and minds of these future tech moguls please check out our volunteer app and apply to become a core team leader. We're excited to meet you and have you join us on this journey to change the face of technology.
~One Girl At A Time~
Imagine the Impact
When we give girls of color the tools to develop their own future, great things are bound to happen. BGC founder Kimberly Bryant can definitely relate. Read what she has to say about girls in STEM fields.
BGC Girls on the Go
Since BGC's launch in 2011, the girls of BlackGirlsCode have eagerly jumped into programming. Have a look at what we've done to support girls in STEM and register for upcoming classes!
Help Us Grow
Together, we can change the face of technology to create opportunities for all. Donate your time and expertise, or make a contribution, or both!
Keep in Touch
We're on the move, but it's easy to keep in touch with BGC via
Twitter, Facebook, and the BGC blog.
Are you a girl who codes? Or know one? Shop the BGC Store. . .
+ MEDIA: Find press releases, images, and media tools.
Get Involved
Do you code? Are you an organizer? Photographer? Just want to help out as we grow and expand to new cities? Sign up to volunteer here.
Want to help us change the world? Join a local core team! See the core team roles,descriptions, and application here.
Join our staff! Apply for job openings here.
Sign up your budding coders below for our next class!


text:
How do I go about getting the old axle out of my Audi? I have both ends loose but I can't seem to get enough room to wiggle the axle out. I have removed the shield from the transmission and took the bolt out of the bottom of the shock.
by A6Don in Dillon, MT on September 19, 2010